Groups address policies for prescribing pain medications
The Drug Enforcement Agency, Last Acts Partnership, and the Pain & Policy Studies Group at the University of Wisconsin have issued a guidance document to address clinical and regulatory issues involving the prescription of controlled substances to treat pain.
The Drug Enforcement Agency, Last Acts Partnership, and the Pain & Policy Studies Group at the University of Wisconsin have issued a guidance document to address clinical and regulatory issues involving the prescription of controlled substances to treat pain.
The guidance contains frequently asked questions and answers for health care providers and law enforcement officials. It is a follow-up to a consensus statement on "Promoting Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act," issued by the three groups in 2001.
For more information, visit www.deadiversion.usdoj.gov/faq.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
